Some Research on Pregnant and Postpartum Women with HIV Is Presented at CROI, But More Trials Are Needed
Pregnant people who are living with or vulnerable to HIV need to be included in clinical trials in order to close our knowledge gaps.
A CROI 2020 roundup of studies on birth control and women living with HIV.
The biggest may be that more of an HIV-positive person’s equally long lifespan will be spent managing comorbidities, one large study found.
March 12, 2020: The impact of age on viral suppression and immunologic recovery; chronic obstructive pulmonary disease risk among older PLWHIV; sex-based differences in older men vs. women; effect of aging on drug-drug interactions.
Treating newborns with antiretroviral therapy in the hours after birth may help put HIV into remission.
Although injectable cabotegravir/rilpivirine is still yet to be approved by the FDA, evidence keeps mounting on the effectiveness of the shot for HIV treatment.
Researchers are happy but cautious, because this isn’t a strategy for most people with HIV.
COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.
A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.